This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Having previously run its AI workloads on premises, the clinical-stage biotechnology company chose Vultr Cloud GPU, a GPU-as-a-service that Athos runs on Dells Nvidia-powered HGX H100 PowerEdge servers to train its homegrown AI models and build its AI-powered precision medicine platform aimed at solving auto-immune and cancerous diseases.
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. While Sana says its approach is applicable to a number of diseases, some of its most advance research is being done around cancer. And like many biotechnology companies it is losing money. stake in Sana.
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo).
Biotechnology and synthetic biology: The swift development of mRNA vaccines in 2020 illustrated biotechs unprecedented speed in delivering transformative products. Attempting advanced applications without digitizing foundational processes first leads to disappointments, too. Some companies just dont know where to begin.
Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).
Sana Biotechnology has a new $50 million tool in its toolbox. SANA intends to file its first investigational new drug application incorporating the new gene editing platform as early as next year, said Harr. The application with the U.S. Sana CEO and president Steve Harr. Sana Photo).
Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. Adaptive Biotechnologies , Absci , and Zymeworks also announced layoffs this year. Sana expects to file its first investigational new drug application (IND) this year with the U.S.
A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.
Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. Next year the companies expect to file an investigational new drug application with the U.S.
Icosavax filed a clinical trial application in Belgium in June for its RSV candidate and plans to initiate trials later this year, according to a company filing with the U.S. Proteomics company Nautilus Biotechnology went public via a SPAC last month and Absci, developing a drug discovery platform, filed to go public just last week.
It is focused initially on immuno-oncology applications. Another Seattle biotech company, Nautilus Biotechnology, announced a $76 million funding round Thursday. The 4-year-old company is developing cytokines that regulate their own activity in response to biomarkers and metabolic signals, said CEO John Mulligan.
And with the availability of a multitude of software solutions to remedy such issues as manufacturing, supply chain, finance, and procurement, the innovations derived from those applications are done by the people , transforming both industries and society. The humanitarian undertaking was accomplished in an astonishing six weeks.
The company aims to file an investigational new drug application for the condition with the U.S. Ainsworth, a veteran biotech exec, has led the company since 2018 when he replaced Matthew Scholz , who founded the company in 2009 and is now CEO of Oisín Biotechnologies.
The work of non-profits such as the Future of Life Institute looks at transformative technology such as AI and biotechnology with the goal of steering it toward benefiting life and away from extreme large-scale risks. These organizations and others can be valuable resources to raise awareness of the risks at hand.
New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. We believe Oisín is well positioned to address this unmet medical need and will continue to explore other applications in tandem,” said Matthew Scholz , Oisín’s CEO and co-founder. Oisín Photos).
Workplace of the Year finalists, clockwise from top left: Adaptive Biotechnologies co-founders Harlan and Chad Robins; the Helion team; Impinj offices in Seattle; Treasury4 team; Blink CEO Karen Clark Cole. This year’s finalists are Adaptive Biotechnologies, Blink, Helion, Impinj and Treasury4. Blink Blink CEO Karen Clark Cole.
Life sciences panelists at Madrona Venture Group’s Intelligent Application Summit. From left: Cyrus Biotechnology CEO Lucas Nivon, Microsoft researcher Jonathan Carlson, Deepcell CEO Maddison Masaeli, and moderator Chris Picardo, a Madrona venture partner. GeekWire Photo / Charlotte Schubert). IPD Image).
Exploring how to best use this strategy for specific applications is now an active area of research, and this is where I expect the next breakthroughs,” said Baker. These include A-Alpha Bio , which recently raised $20 million , and Cyrus Biotechnology , which recently inked a deal worth up to $1.5 billion with immune biotech Selecta.
Adaptive Biotechnologies Photo). Chad Cohen will step down as CFO of Adaptive Biotechnologies on Feb. Absci will develop enzymes matched to biomanufacturing applications at Merck. Chad Cohen. Prior to joining Adaptive in 2015, Cohen was CFO of Zillow Group.
Sana Biotechnology raised $587.5 While Sana says its gene editing technology will be applicable to a number of diseases, some of its most advanced research is being done around cancer. Sana’s gene editing tech could provide treatments for a number of diseases. Image: IPO filing).
In an article published in Nature Biotechnology , researchers in the Vascular Bionics Laboratory at the University of Melbourne led by neurologist Thomas Oxley, M.D.,
Where quantum development is, and is heading In the meantime, the United Nations designation recognizes that the current state of quantum science has reached the point where the promise of quantum technology is moving out of the experimental phase and into the realm of practical applications.
Inspired by biological respiration, their electrochemical system uses renewable energy and requires minimal land, making it scalable and versatile for various applications. Hottest Series A: Mission Zero Mission Zero is advancing direct air capture (DAC) to remove CO₂ from the atmosphere efficiently.
According to the 2023 State of the CIO , IT leaders are looking to shore up competencies in key areas such as cybersecurity (39%), application development (30%), data science/analytics (30%), and AI/machine learning (26%).
These scams employ deceptive tactics, preying on students' aspirations for job opportunities in the healthcare, biosciences, and biotechnology sectors, among others. The threat actors used email lures with job-themed subject lines, appearing to come from reputable organizations related to biosciences, healthcare, and biotechnology.
The office will focus on artificial intelligence, cloud-based tools, and other technology applications. But it will also play a big role in growing the company’s capabilities in applying artificial intelligence to biomedical applications, said Miller.
As biotechnology company Regeneron was rolling out Acrobat Sign to streamline processes, Global Head of Application Services & Intelligent Automation Jai Gulati said, “Adoption is the key to any new technology.
Some 7,587 freshman applicants to the University of Washington for next year picked the prestigious Paul G. Strella Biotechnology Co-founder and CEO Katherine Sizov won GeekWire’s Elevator Pitch startup competition at the 2022 GeekWire Summit, with a unique sensing technology that reduces food waste by determining what? Doug Baldwin.
Pourhassan allegedly directed Kazempour to submit an application to the FDA to market leronlimab as an HIV treatment — even though the application was incomplete and the pair allegedly knew that the FDA would refuse to review it. The company then touted the “complete” application in a press release, according to the indictment.
Cyrus Biotechnology, for instance, recently raised $18 million and has more than 90 drug company partnerships, A-Alpha Bio has raised $20 million , and Icosavax went public this year with a $180 million raise to advance its vaccines for COVID-19 and other conditions. Seattle is peppered with IPD startups.
Startups in the field include IPD spinout Cyrus Biotechnology, which can engineer therapeutic proteins with properties such as greater stability in the body. “Knowing a protein’s structure is the first step to understanding its function, drug discovery, and many other applications,” Baek told GeekWire. (UW IPD Image).
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Mallick and Patel teamed up to create Nautilus Biotechnology. Other applications include diagnostics and health monitoring — knowing which drug a patient should take based on their proteome, for example, or predicting potential health problems.
Sprague spent the past seven years at Seattle application delivery giant F5, and became an executive vice president in 2019. Sana Biotechnology, and Indiana University’s Kelley School of Business. (HackerOne Photo) Kara Sprague , chief product officer at F5, was named CEO at San Francisco-based cybersecurity company HackerOne.
Nvidia AI Foundations is a family of cloud services with which enterprises will be able to build their own large language models (LLMs), the technologies at the heart of generative AI systems, and run them at scale, calling them from enterprise applications via Nvidia’s APIs.
The company’s investigation similarly concluded that a June patent issued for ATH-1017 did not cite the papers containing the altered images, nor did the underlying patent application. One of the WSU papers including her research was published as late as 2014, while Kawas was the CEO of the company, formerly called M3 Biotechnology.
Nautilus Biotechnology hired Karl Voss as vice president of life sciences research and development. Based in Seattle, Nautilus Biotechnology is led by Isilon Systems co-founder Sujal Patel and went public via a SPAC merger in June. Instabase provides an app store for business and enterprise applications. research center.
There’s a fourth biotech company being born, said Olson, who also heads the Invent at Seattle Children’s Postdoctoral Scholars Program to train students underrepresented in science for careers in biotechnology. You should really have a product and the key proof of concept experiments done.
She became the first person to produce a tangible and applicable manufactured enzyme from Nobel Prize-winning methods. “The applications are almost limitless.” She was on the forefront of the biotechnology future.
A previously unknown Seattle startup, founded by semiconductor and technology industry veterans, says it has developed an energy-efficient chip capable of running advanced AI applications on lightweight, wireless augmented reality headsets that will operate all day without recharging. … Read More. … Read More. … Read More.
GeekWire Photo / Charlotte Schubert) Potential applications include assessing the actions of therapeutic cells and improving their design. Another application might be to track body-wide how a mouse responds over time to specific drugs or other perturbations. The Write Team develops the technology for recording to DNA.
On the molecular level, the animal seems to have a cheat code for life: It can regenerate its limbs and vital organs, an ability researchers are desperate to better understand for medical applications. Read more.
” Temporal is a cloud application company that achieved unicorn status in 2022, reaching a valuation of $1.5 Nitin Sood , chief commercial officer of the MRD business at Adaptive Biotechnologies, is departing. “She brings a unique breadth and depth of enterprise experience and leadership skills to our team.”
F5 Photos) — Seattle-based application security and delivery giant F5 announced two new executive appointments this week: Lyra Schramm , the company’s new chief people officer, and Kunal Anand , chief technology officer. F5 Chief People Officer Lyra Schramm (left) and Chief Technology Officer Kunal Anand. (F5
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content